EJC paediatric oncology最新文献

{"title":"European clinical practice recommendations for the diagnosis and treatment of paediatric pineal tumours","authors":"Sarita Depani ,&nbsp;Alexandre Vasiljevic ,&nbsp;Martin Mynarek ,&nbsp;Christelle Dufour ,&nbsp;Elke Pfaff ,&nbsp;Ata Ur Maaz ,&nbsp;Léa Guerrini-Rousseau ,&nbsp;Francois Doz ,&nbsp;Martin Hasselblatt ,&nbsp;Thankamma Ajithkumar ,&nbsp;Kristian Aquilina ,&nbsp;Martin U. Schuhmann ,&nbsp;Eelco Hoving ,&nbsp;Anna Tietze ,&nbsp;Ulrike Löbel ,&nbsp;Barry Pizer ,&nbsp;Katja von Hoff ,&nbsp;On behalf of the SIOP-Europe Rare Embryonal and Sarcomatous Tumours (REST) group","doi":"10.1016/j.ejcped.2025.100217","DOIUrl":"10.1016/j.ejcped.2025.100217","url":null,"abstract":"<div><div>Paediatric tumours of the pineal region are rare CNS tumours accounting for 3% of brain tumours in children and adolescents; the majority of which are germ cell tumours. This review focuses on pineal parenchymal tumours (pineoblastoma, pineal parenchymal tumour of intermediate differentiation, pineocytoma) and those specifically arising in the pineal region (papillary tumours of the pineal region, desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant and pineal cyst), which together account for up to a third of pineal tumours. In recent years, the diagnostic classification of these specific tumour-types has been refined by the integration of molecular pathology. Given the differences in grade, tumour biology and clinical behaviour, an accurate integrated neuropathological diagnosis is essential in deciding an appropriate treatment strategy which can range from surgery only to intensive multi-modal therapies. The most common of these tumours in children is WHO Grade 4 pineoblastoma, where specific molecular subgroups occurring in very young patients are difficult to treat successfully. Further challenges include the anatomical position and associated surgical risk together with a lack of molecularly annotated clinical data and consequent limited evidence to guide the therapeutic approach due to their rarity. These guidelines aim to provide a framework for diagnosis, prognostication and management based on current literature and expert opinion.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100217"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parental role in paediatric cancer treatment decision making at Tikur Anbessa Specialized Hospital, Ethiopia: A mixed method study","authors":"Daniel Betemariem ,&nbsp;Leul Deribe ,&nbsp;Aklil Hailu ,&nbsp;Haileyesus Adam ,&nbsp;Nataliya Berbyuk Lindström","doi":"10.1016/j.ejcped.2025.100218","DOIUrl":"10.1016/j.ejcped.2025.100218","url":null,"abstract":"<div><h3>Background</h3><div>Parental preferences for involvement in treatment decision-making (TDM) in pediatric oncology can vary among passive, collaborative, and active roles, influenced by various factors. This study investigates the parental role in TDM for children with cancer in Ethiopia and identifies the key determinants of this role.</div></div><div><h3>Methods</h3><div>This research employs a mixed-methods approach, combining a cross-sectional survey and phenomenological interviews. A total of 167 parents of children with cancer participated in the survey, utilizing the Control Preference Scale for Pediatrics (CPS-P) and the Krantz Health Opinion Survey (KHOS) to assess parental roles in TDM. Additionally, 11 in-depth interviews were conducted with selected parents. Logistic regression and thematic analysis were used to analyze the quantitative and qualitative data, respectively.</div></div><div><h3>Results</h3><div>The findings reveal that Ethiopian parents predominantly prefer a passive role in TDM. Trust in healthcare providers and parental information preferences emerged as statistically significant predictors of this passive involvement. Other factors influencing parental decision-making included the quality of the parent-provider relationship, the child’s clinical condition, parental beliefs about TDM, and knowledge of cancer.</div></div><div><h3>Conclusions</h3><div>This study offers valuable insights into the parental role in TDM within Ethiopian pediatric oncology care, an area previously unexplored. Understanding parents’ preferences in TDM is crucial for Ethiopian healthcare providers to align communication and amplify patient voices. The findings highlight the need to promote more active parental involvement in TDM by facilitating educational sessions, developing parental education guidelines, and providing accessible cancer information across diverse regions of the country.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100218"},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in care delivery for children and adolescents with cancer in Europe – Results from the SIOPE OCEAN project","authors":"Maria Otth ,&nbsp;Teresa de Rojas ,&nbsp;Kerstin K. Rauwolf ,&nbsp;Miguel Martins ,&nbsp;Uta Dirksen ,&nbsp;Delphine Heenen ,&nbsp;Lejla Kameric ,&nbsp;Pamela Kearns ,&nbsp;Ruth Ladenstein ,&nbsp;Cormac Owens ,&nbsp;Caroline Queiroz ,&nbsp;Richard Sullivan ,&nbsp;Carmelo Rizzari ,&nbsp;Gilles Vassal ,&nbsp;on behalf of the European Society of Pediatric Oncology (SIOPE)","doi":"10.1016/j.ejcped.2025.100219","DOIUrl":"10.1016/j.ejcped.2025.100219","url":null,"abstract":"<div><h3>Background</h3><div>Variations in access to high quality clinical care and research are global issues for children and adolescents with cancer. Therefore, SIOPE launched the OCEAN project (Organisation of Care and rEsearchfor children with cANcer in Europe) to map the landscape for both these domains. Here we present the clinical care part.</div></div><div><h3>Methods</h3><div>We used a mixed methods approach to map epidemiological data and self-reported care aspects. We described cancer incidence in children and adolescents aged 0–24 years. For the qualitative part, we performed a survey covering a broad range of care aspects. We used descriptive statistics to present the results.</div></div><div><h3>Results</h3><div>The cancer incidence across Europe was 15/100’000 and 26/100’000 in those aged 0–14 and 15–24 years respectively in 2022. Representatives from 37 countries responded to the survey. These countries cover 385 centres treating cancer in children and adolescents, including 18 cancer centres. Highly specialized treatment modalities and care structures are not available in every country. Public health insurances reimburse standard of care treatments in most countries (35/37); however, they do not cover all costs and additional funding is reported to be needed in up to one fifth of countries.</div></div><div><h3>Discussion</h3><div>Differences exist in many aspects of clinical care of the 37 countries, but the key aspects are delivered in all countries. We interpret that highly specialised diagnostic tools and treatment modalities must be concentrated in selected centres. A well-functioning national and international collaboration must be guaranteed to give all children and adolescents with cancer equal access to best clinical care.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100219"},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143419439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An assessment of circulating biomarkers and germline genetic variants in predicting chemotherapy associated mucositis in Ewing sarcoma","authors":"Pawan Gulati ,&nbsp;Vickyanne Carruthers ,&nbsp;Claire Hutton ,&nbsp;Chloe Cassidy ,&nbsp;Edward B. Amankwatia ,&nbsp;Séréna Pascual ,&nbsp;Electra Florence ,&nbsp;Tsegay G. Gebru ,&nbsp;Andrea L. Jorgensen ,&nbsp;Alastair Greystoke ,&nbsp;Guy Makin ,&nbsp;Martin G. McCabe ,&nbsp;Daniel B. Hawcutt ,&nbsp;Gareth J. Veal ,&nbsp;David Jamieson","doi":"10.1016/j.ejcped.2025.100216","DOIUrl":"10.1016/j.ejcped.2025.100216","url":null,"abstract":"<div><h3>Background</h3><div>Treatment of Ewing sarcoma is associated with severe toxicities including chemotherapy-induced mucositis. Here we investigated the role of circulating biomarkers and genetic factors in predicting mucositis severity in Ewing sarcoma.</div></div><div><h3>Methods</h3><div>Blood samples were collected from 111 Ewing sarcoma patients during treatment. Circulating total CK18 and FLT3 ligand concentrations were measured in plasma. Germline DNA was used to investigate associations between genetic variants and mucositis severity.</div></div><div><h3>Results</h3><div>An increase in median tCK18 levels was observed during cycle 1, from 189 (86−736) U/L at cycle 1 day 1 pre-chemotherapy to 311 (141–1138) U/L on cycle 1 day 2–5 (p = 0.0001). Patients experiencing a ≥ 1.3-fold increase in tCK18 at 48–120 hours after administration of the first cycle had a higher likelihood of developing grade 3 mucositis in any cycle (p = 0.044). Genetic analysis revealed an association between a gene set associated with chemotherapy induced severe mucositis and differentially expressed genes set for minor salivary gland (p = 4.12 ×10⁻⁴) and esophageal mucosa (p = 1.55 ×10⁻⁵).</div></div><div><h3>Discussion</h3><div>Early increases in circulating CK18 levels correlated with grade 3 mucositis. Genome-wide association analysis highlighted genes that may be associated with mucositis pathology, offering insights into biological mechanisms underlying susceptibility.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100216"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to use monoclonal antibody-based therapy in ALL","authors":"Erica Brivio ,&nbsp;Sujith Samarasinghe","doi":"10.1016/j.ejcped.2025.100214","DOIUrl":"10.1016/j.ejcped.2025.100214","url":null,"abstract":"<div><div>Acute Lymphoblastic Leukemia (ALL) represents a significant challenge in haematology, particularly due to its aggressive nature, high relapse rates in adults and toxicity of treatment. Over the past decade, monoclonal antibody (MoAb)-based therapies have emerged as a promising approach to target specific antigens on leukemic cells, offering higher specificity, reduced toxicity, and improved response rates. This article provides an in-depth examination of the journey from laboratory research to clinical application, discussing mechanisms of action, key MoAbs used in ALL, their clinical applications, current challenges, and potential future directions in antibody-based therapy.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100214"},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143171720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis","authors":"Pedro C.A. Reis ,&nbsp;João Evangelista Ponte Conrado ,&nbsp;Mariana Macambira Noronha ,&nbsp;Luís Felipe Leite da Silva ,&nbsp;Erick Figueiredo Saldanha ,&nbsp;Jonathan Metts","doi":"10.1016/j.ejcped.2025.100215","DOIUrl":"10.1016/j.ejcped.2025.100215","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint blockade (ICB) has changed the treatment landscape for many types of adult cancer. However, for children, adolescents, and young adults (CAYAs) clinical experience lags behind that of adults. Therefore, we performed a systematic review and meta-analysis to evaluate the safety and efficacy of ICB in the CAYA population.</div></div><div><h3>Methods</h3><div>We searched PubMed, Embase, and Cochrane Library databases for clinical trials evaluating ICB therapies for cancer in CAYA patients. We pooled the incidences of treatment-related adverse events (TRAEs), objective response rates (ORRs), stable disease (SD), and their corresponding confidence intervals (CIs). For the ORR and TRAE endpoints, we performed a subgroup analysis of each drug (PD-1, PD-L1, and CTLA-4) and tumor type.</div></div><div><h3>Results</h3><div>15 trials were included, comprising 797 patients (median age ranging from 6.5 to 16.0 years). All-grade TRAE rate of 66 % was found (95 % CI 60–71), while the proportion of grade 3/4 TRAEs was 19 % (95 % CI 14–27). For tumor type subgroup analysis of all-grade TRAEs and grade 3/4 TRAEs, solid tumors had the highest rates, 92 % (95 % CI 41–99) and 32 % (95 % CI 11–63), respectively. Fatigue, anemia, and nausea were the most frequently reported TRAEs. The ORR was 13 % (95 % CI 5–27). In subgroup analyses, PD-1 inhibitors and Hodgkin Lymphoma had the highest ORR, with 25 % (95 % CI 8–56) and 59 % (95 % CI 23–87), respectively. SD was noted in 21 % (95 % CI 14–30) of patients.</div></div><div><h3>Conclusions</h3><div>Overall, ICB is well tolerated in CAYA patients with different cancer types, and certain subsets of CAYA cancer are ICB-responsive.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100215"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UNCAN.eu, the European platform to understand cancer, and childhood cancers","authors":"Gilles Vassal","doi":"10.1016/j.ejcped.2024.100212","DOIUrl":"10.1016/j.ejcped.2024.100212","url":null,"abstract":"<div><div>The EU will create the UNCAN.eu platform, a European Federated Data Hub to provide access to high -quality cancer research data in order to better understand cancer and drive innovation. A Coordinated and Supported Action has delivered to the EU in November 2023 a blueprint of the UNCAN.eu including a strategic roadmap, the needed data and infrastructures, the interactions with all EU infrastructures and initiatives, a governance, a financial plan and a budget. SIOP Europe and CCI Europe were partners of the consortium to address the needs of children, adolescents and young adult with cancer as well as childhood cancer survivors. This article summarizes the blueprint proposal and how the UNCAN.eu could facilitate the implementation of a European Childhood Cancer Data Strategy through facilitated access to comprehensive childhood cancer data (molecular data, imaging, pathology, clinical trials and real world data) to accelerate innovation for children, adolescents and young adults with cancer.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100212"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparedness of European pediatric oncologists to integrate AI in the clinical routine","authors":"Alberto E. Tozzi ,&nbsp;Diana Ferro ,&nbsp;Ileana Croci ,&nbsp;Francesco Fabozzi ,&nbsp;Angela Mastronuzzi","doi":"10.1016/j.ejcped.2024.100213","DOIUrl":"10.1016/j.ejcped.2024.100213","url":null,"abstract":"<div><h3>Background</h3><div>Artificial intelligence (AI) holds promise in pediatric oncology, yet its full potential faces challenges. We undertook a survey aimed at assessing the viewpoints of European pediatric oncologists delving into their perceptions and expectations regarding the potential influence of AI in their clinical workflows.</div></div><div><h3>Method</h3><div>We conducted a survey by means of four hypothetical scenarios using AI and the Shinners Artificial Intelligence Perception (SHAIP) tool to assess healthcare professionals' perceptions of AI in pediatric oncology. We performed multinomial logistic regression to explore associations of responses to clinical scenarios with age and SHAIP scores.</div></div><div><h3>Results</h3><div>We obtained 140 responses and the analysis was performed on 108. The SHAIP questionnaire mean total score was 3.29 (SD 0.93) for the professional impact, and 2.37 (SD 0.61) for preparedness. Regarding the clinical scenarios, 34.9 % of respondents would ask for a procedure for confirming their diagnosis in case of discrepancy between AI decision support and human diagnosis; 55.8 % would be concerned about the generalizability an AI decision support system in case of lack of data from certain geographic areas during algorithm training; 47.6 % would feel uncomfortable in the informed consent process for an AI intervention; 10.2 % would no longer trust AI in case of a cyberattack affecting AI support for diagnosis.</div></div><div><h3>Discussion</h3><div>This survey underscores the importance of AI tools in pediatric oncology that incorporate human oversight in clinical decision-making and training AI algorithms with diverse and representative data. Our findings suggest that pediatric oncologists may not be adequately prepared for the seamless integration of AI in clinical practice.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100213"},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143171719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Local application of sodium thiosulfate as an otoprotectant for cisplatin-exposed patients – A narrative literature review to explore the potential benefit for children with cancer","authors":"Nienke Streefkerk ,&nbsp;Amirhossein Masroor ,&nbsp;James I. Geller ,&nbsp;Martine van Grotel ,&nbsp;Marc Ansari ,&nbsp;Eric Bouffet ,&nbsp;Archie Bleyer ,&nbsp;Brice Fresnau ,&nbsp;Michael Sullivan ,&nbsp;Alwin D.R. Huitema ,&nbsp;Alexander E. Hoetink ,&nbsp;Per Kogner ,&nbsp;Rudolf Maibach ,&nbsp;Allison F. O’Neill ,&nbsp;Vassilios Papadakis ,&nbsp;Kaukab M. Rajput ,&nbsp;Gareth J. Veal ,&nbsp;Penelope R. Brock ,&nbsp;Annelot J.M. Meijer ,&nbsp;Marry M. van den Heuvel-Eibrink","doi":"10.1016/j.ejcped.2024.100211","DOIUrl":"10.1016/j.ejcped.2024.100211","url":null,"abstract":"<div><h3>Background</h3><div>Ototoxicity is a highly prevalent, serious, and irreversible side effect in cisplatin-treated childhood cancer patients, which can significantly impact speech-language development, psychosocial development, and quality of life. In this respect, the development and implementation of reliable and safe otoprotectants is urgently needed. Sodium thiosulfate (STS*) is an otoprotective drug, recently approved for intravenous administration in cisplatin-treated children with non-disseminated cancer. Intratympanic STS application has been developed as a potential strategy to reduce systemic exposure. To explore potential opportunities for this approach, we have reviewed available literature addressing efficacy, safety, and pharmacokinetics of local STS administration.</div></div><div><h3>Methods</h3><div>A PubMed search, focused on clinical and pre-clinical efficacy, safety, and pharmacokinetics of local STS application in cisplatin-exposed subjects of all ages was performed.</div></div><div><h3>Findings</h3><div>From 256 studies, ten studies met the inclusion criteria, including seven preclinical studies, and three clinical studies. Four studies (two preclinical, two clinical) which included pharmacokinetic data, showed that locally administered STS was associated with low systemic serum STS levels. Preclinical studies in guinea pigs showed a significant protective effect on outer hair cell loss or hearing function. However, two clinical trials in adults did not show convincing evidence of otoprotection, by locally administered STS.</div></div><div><h3>Interpretation</h3><div>Preclinical studies suggest a potential benefit of locally administered STS, however clinical evidence for a significant otoprotective effect is not yet available. The burden and potential sequalae of repeated intratympanic procedures in children, together with the low level of evidence of efficacy, currently limited to pre-clinical data, suggests that further study and potentially improved technology to apply local STS is required for childhood cancer patients receiving cisplatin.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100211"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143171718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European standard clinical practice recommendations for paediatric high-grade gliomas","authors":"Elwira Szychot ,&nbsp;Géraldine Giraud ,&nbsp;Darren Hargrave ,&nbsp;Dannis van Vuurden ,&nbsp;Jacques Grill ,&nbsp;Veronica Biassoni ,&nbsp;Maura Massimino ,&nbsp;André O. von Bueren ,&nbsp;Rejin Kebudi ,&nbsp;Maria João Gil-da-Costa ,&nbsp;Sophie Veldhuijzen van Zanten ,&nbsp;Simon Bailey ,&nbsp;Michael Karremann ,&nbsp;Stephanie Bolle ,&nbsp;Thankamma Ajithkumar ,&nbsp;Mechthild Krause ,&nbsp;Yasmin Lassen-Ramshad ,&nbsp;Geert Janssens ,&nbsp;Giovanni Morana ,&nbsp;Ulrike Löbel ,&nbsp;Christof M. Kramm","doi":"10.1016/j.ejcped.2024.100210","DOIUrl":"10.1016/j.ejcped.2024.100210","url":null,"abstract":"<div><div>Paediatric high-grade gliomas (pedHGGs) are highly invasive brain tumours accounting for approximately 15 % of all central nervous system (CNS) tumours in children and adolescents. The outcome for these tumours is generally poor with 5-year survival rates of less than 20 %. Despite improved biological insights into pedHGGs and the promise of more effective therapies, little progress has been made in the effective treatment and the outcome of these tumours over the last four decades. Much of the evidence for the use of chemotherapy in pedHGGs is extrapolated from adult data, and the evidence for its use in the paediatric population is still weak. This guideline was written by members of the SIOPE HGG Working Group as part of the European Standard Clinical Practice (ESCP) Project of the European Reference Network for Paediatric Oncology, ERN PaedCan. The guideline aims to integrate available evidence-based and expert opinion-based information to assist healthcare professionals in the management of pedHGGs and in an attempt to provide equity in healthcare reflecting the varying resources of each European country.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"5 ","pages":"Article 100210"},"PeriodicalIF":0.0,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}